

( (S (NP-SBJ Johnson & Johnson)
     (VP reported
         (NP (NP (NP a (ADJP 10 %) rise)
                 (PP-LOC in
			 (NP third-quarter net income))
                 (PP on
                     (NP a 12 % sales increase)))
             -
             (NP (NP results)
                 (SBAR (WHNP-2 that)
                       (S (NP-SBJ-1 *T*-2)
                          (VP were
                              (VP driven
                                  (NP *-1)
				  (PP (ADVP particularly)
				      by
                                      (NP-LGS (NP new products)
					      (PP including
						  (NP (NP pharmaceuticals)
						      and
						      (NP (NP the company 's)
							  professional operations))))))))))))
     .))
( (S (NP-SBJ (NP Net)
             (PP for
                 (NP (NP the
			 (NP (NP New Brunswick)
			     ,
			     (NP N.J.)
			     ,)
			 maker)
                     (PP of
                         (NP health-care products)))))
     (VP climbed
         (PP-DIR to
		 (NP (NP (QP $ 265 million) *U*)
		     , or
		     (NP (NP 80 cents)
			 (NP-ADV a share))))
         ,
         (PP-DIR from
		 (NP (NP (NP (QP $ 240 million) *U*)
			 , or
			 (NP (NP 71 cents)
			     (NP-ADV a share))
			 ,)
		     (PP-TMP in
			     (NP the year-earlier period)))))
     .))
( (S (NP-SBJ Sales)
     (VP rose
         (PP-DIR to
		 (NP (QP $ 2.45 billion) *U*))
         (PP-DIR from
		 (NP (QP $ 2.2 billion) *U*)))
     .))
( (S (NP-SBJ-1 The year-ago per-share earnings)
     (VP are
         (VP adjusted
             (S (NP-SBJ *-1)
                (VP to
                    (VP reflect
                        (NP (NP a 2-for-1 stock split)
			    (NP-TMP last May)))))))
     .))
( (S (PP-LOC In
	     (NP a statement))
     ,
     (NP-SBJ (NP Ralph S. Larsen)
             ,
             (NP (NP chairman)
                 and
                 (NP chief executive officer))
             ,)
     (VP said
         (SBAR 0
               (S (NP-SBJ the company)
                  (VP was
                      (ADJP-PRD pleased
                                (PP with
                                    (NP its third-quarter sales performance)))
		      ,
		      ``
		      (PP (ADVP especially)
			  in
			  (NP (NP light)
			      (PP of
				  (NP (NP (NP the extremely competitive environment)
					  (PP-LOC in
						  (NP domestic consumer markets)))
				      and
				      (NP (NP the negative impact)
					  (PP of
					      (NP (NP unfavorable exchange rates)
						  (NP-TMP this quarter))))))))))))
     . 
     ''))
( (S (NP-SBJ (NP David J. Lothson)
             ,
             (NP (NP an industry analyst)
                 (PP for
                     (NP PaineWebber Group Inc.)))
             ,)
     (VP said
         (SBAR 0
               (S (NP-SBJ (NP Johnson & Johnson 's)
                          results)
                  (VP (ADVP-EXT slightly)
                      exceeded
                      (NP (NP his expectations)
                          (PP for
                              (NP the third quarter)))))))
     .))
( (S (PP-LOC In
	     (NP New York Stock Exchange composite trading))
     (NP-TMP yesterday)
     ,
     (NP-SBJ Johnson & Johnson shares)
     (VP fell
         (NP-EXT 37.5 cents)
         (PP-DIR to
		 (NP $ 54.625 *U*)))
     .))
( (S (NP-SBJ Mr. Larsen)
     (VP noted
         (NP (NP `` substantial sales growth '')
             (PP for
                 (NP (NP the (ADJP recently introduced) Acuvue disposable contact lens)
                     and
                     (NP (NP Hismanal)
                         ,
                         (NP a once-a-day antihistamine))))))
     .))
( (S (S-TPC-2 (NP-SBJ (NP (NP Eprex)
			  ,
			  (VP used
			      (NP *)
			      (PP by
				  (NP-LGS (NP dialysis patients)
					  (SBAR (WHNP-1 who)
						(S (NP-SBJ *T*-1)
						   (VP are
						       (ADJP-PRD anemic))))))))
		      , and
		      (NP (NP Prepulsid)
			  ,
			  (NP a gastro-intestinal drug))
		      ,)
	      (VP did
		  (ADVP-MNR well)
		  (ADVP-LOC overseas)))
     ,
     (NP-SBJ he)
     (VP said
	 (SBAR 0
	       (S *T*-2)))
     .))
( (S (S-TPC-3 (PP Despite
		  (NP (NP health-care cost controls)
		      and
		      (NP (NP programs)
			  (SBAR (WHNP-2 0)
				(S (NP-SBJ *T*-2)
				   (VP to
				       (VP hold
					   (PRT down)
					   (NP inventory))))))))
	      ,
	      (NP-SBJ (NP the professional division)
		      ,
		      (SBAR (WHNP-1 which)
			    (S (NP-SBJ *T*-1)
			       (VP makes
				   (NP (NP products)
				       (PP including
					   (NP (NP sutures)
					       and
					       (NP surgical stapling equipment)))))))
		      ,)
	      ``
	      (VP achieved
		  (NP solid growth)))
     ,
     ''
     (NP-SBJ Johnson & Johnson)
     (VP said
	 (SBAR 0
	       (S *T*-3)))
     .))
( (S But
     (NP-SBJ domestic consumer sales)
     (VP slipped
         (NP-EXT 1.2 %)
         (PP for
             (NP the quarter))
         ,
         (PP-DIR to
		 (NP (QP $ 490 million) *U*))
         (PP-DIR from
		 (NP (QP $ 496 million) *U*)))
     .))
( (S (NP-SBJ The company)
     (VP cited
         (NP (NP (NP softness)
                 (PP-LOC in
			 (NP the retail health and beauty aids category)))
             , 
	     `` 
	     as well as
             (NP (NP the intense competition)
                 (PP-LOC in
			 (NP (NP the company 's)
			     sanitary protection product line)))))
     . 
     ''))
( (S (S-TPC-2 (NP-SBJ Overseas sales)
	      (VP were
		  (ADJP-PRD stronger)
		  ,
		  (PP-PRP (ADVP principally)
			  because of
			  (NP (NP a rebound)
			      (PP-LOC in
				      (NP (NP Brazil)
					  ,
					  (SBAR (WHADVP-1 where)
						(S (NP-SBJ economic turmoil)
						   (VP had
						       (VP hurt
							   (NP year-earlier results)
							   (ADVP-LOC *T*-1)))))))))))
     ,
     (NP-SBJ Johnson & Johnson)
     (VP said
	 (SBAR 0
	       (S *T*-2)))
     .))
( (S (NP-SBJ (NP Mr. Lothson)
             (PP of
                 (NP PaineWebber)))
     (VP said
         (SBAR 0
               (S (NP-SBJ (NP the company 's)
                          sales pace)
                  (VP has
                      (VP been
                          (VP picking
                              (ADVP-CLR up)
			      (SBAR-PRP (ADVP largely)
					because
					(S (NP-SBJ (NP the effect)
						   (PP of
						       (NP unfavorable exchange rates)))
					   (VP has
					       (VP been
						   (VP easing
						       --
						       (NP-ADV (NP a pattern) 
							       (VP continuing
								   (NP-TMP this quarter))))))))))))))
     .))
( (S (NP-SBJ He)
     (VP cautioned
	 ,
         (ADVP however)
         ,
         (SBAR that
               (S (NP-SBJ a `` tough tax-rate comparison '')
                  (VP may
                      (VP slow
                          (NP (NP (NP the company 's)
				  earnings growth)
                              (PP for
                                  (NP the current quarter))))))))
     .)) 
( (S (S-TPC-1 (PP For
		  (NP (NP last year 's)
		      fourth quarter))
	      ,
	      (NP-SBJ (NP the company 's)
		      tax rate)
	      (VP was
		  (NP-PRD (QP less than 20) %)))
     ,
     (NP-SBJ he)
     (VP said
	 (SBAR 0
	       (S *T*-1)))
     .))
( (S-2 (SBAR-ADV While
		 (S (NP-SBJ the third period)
		    (VP contained
			(NP no major surprises))))
       (PRN ,
	    (S (NP-SBJ Mr. Lothson)
	       (VP said
		   (SBAR 0
			 (S *T*-2))))
	    ,)
       (NP-SBJ the results)
       (VP show
	   (SBAR (WHADJP-1 how
			   sensitive)
		 (S (NP-SBJ the multinationals)
		    (VP can
			(VP be
			    (ADJP-PRD *T*-1)
			    (PP to
				(NP (NP developments)
				    (PP-LOC in
					    (NP (NP a single country)
						such as
						(NP Brazil))))))))))
       .))
( (S (NP-SBJ He)
     (ADVP also)
     (VP questioned
         (SBAR whether
               (S (NP-SBJ-1 (NP recent gains)
                            (PP-LOC in
				    (NP that country)))
                  (VP can
                      (VP be
                          (VP sustained
                              (NP *-1)))))))
     .))
( (S (NP-SBJ-4 The following issues)
     (VP were
	 (ADVP-TMP recently)
	 (VP filed
	     (NP *-4)
	     (PP-CLR with
		     (NP the Securities and Exchange Commission))))
     :))
( (NP (NP Bergen Brunswig Corp.)
      ,
      (NP (NP proposed offering)
	  (PP of
	      (NP liquid yield option notes)))
      ,
      (PP via
	  (NP Merrill Lynch Capital Markets))
      .))
( (NP (NP Columbia Gas System Inc.)
      ,
      (NP (NP shelf offering)
	  (PP of
	      (NP (NP (QP up to $ 200 million) *U*)
		  (PP of
		      (NP debentures)))))
      .))
( (NP (NP Laserscope)
      ,
      (NP (NP initial offering)
	  (PP of
	      (NP (NP 1,656,870 common shares)
		  ,
		  (SBAR (WHPP-2 of
				(WHNP which))
			(S (S (NP-SBJ-3 (NP 1,455,000 shares)
					(PP *T*-2))
			      (VP are
				  (S (NP-SBJ-1 *-3)
				     (VP to
					 (VP be
					     (VP sold
						 (NP *-1)
						 (PP-4 by
						       (NP-LGS the company))))))))
			   and
			   (S (NP-SBJ=3 (NP 201,870)
					(PP *T*-2))
			      (PP=4 by
				    (NP-LGS holders)))))))
	  ,
	  (PP via
	      (NP (NP Alex . Brown & Sons Inc.)
		  and
		  (NP Volpe , Covington & Welty))))
      .))
( (NP (NP TeleVideo Systems Inc.)
      ,
      (NP (NP proposed offering)
	  (PP of
	      (NP (NP 1,853,735 common shares)
		  ,
		  (SBAR (WHNP-1 0)
			(S (NP-SBJ-2 *T*-1)
			   (VP to
			       (VP be
				   (VP sold
				       (NP *-2)
				       (PP by
					   (NP-LGS holders))))))))))
      .))
( (NP (NP Western Gas System Inc.)
      ,
      (NP (NP initial offering)
	  (PP of
	      (NP (NP 3,250,000 common shares)
		  ,
		  (SBAR (WHPP-1 of
				(WHNP which))
			(S (NP-SBJ-3 (NP 3,040,000 shares)
				     (PP *T*-1))
			   (VP will
			       (VP be
				   (VP sold
				       (NP *-3)
				       (PP-2 by
					     (NP-LGS the company)))))
			   and
			   (S (NP-SBJ=3 (NP 210,000)
					(PP *T*-1))
			      (PP=2 by
				    (NP a holder)))))))
	  ,
	  (PP via
	      (NP (NP Prudential-Bache Capital Funding)
		  ,
		  (NP Smith Barney)
		  ,
		  (NP Harris Upham & Co.)
		  and
		  (NP Hanifen , Imhoff Inc))))
      .))
